Resectable pancreatic cancer needs surgery, then chemotherapyBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7441.661-a (Published 18 March 2004) Cite this as: BMJ 2004;328:661
- Scott Gottlieb
- New York
Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas treatment with chemoradiotherapy has a negative effect on survival, the results of a new study, in the New England Journal of Medicine, show. The negative effect of chemoradiotherapy was thought to be due to the fact that it delayed the administration of chemotherapy.
Pancreatic cancer, with an overall five year survival rate ranging from 0.4% to 4%, has a poor prognosis and is one of the top 10 causes of death from cancer in the Western world. Previous studies have shown that surgical …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial